Araştırma Makalesi
BibTex RIS Kaynak Göster

Levels of Serum and Urine Catecholaminergic and Apelinergic System Members in Acute Ischemic Stroke Patients

Yıl 2023, Cilt: 18 Sayı: 3, 86 - 94, 20.11.2023
https://doi.org/10.17517/ksutfd.1168625

Öz

Objective: To compare levels of catecholaminergic system members, renalase, cerebellin, and their substrates, epinephrine, norepinephrine, and dopamine, and apelinergic system members, apelin, elabela, and nitric oxide in the blood and urine of patients with acute ischemic stroke and healthy controls.
Materials and Methods: 42 patients with acute ischemic stroke and 42 age and sex-matched healthy controls were included in the study. Blood and urine samples were collected simultaneously and within the first 24 hours after the onset of acute stroke clinical manifestations and were measured using an ELISA method.
Results: The levels of serum and urine cerebellin, renalase, epinephrine, norepinephrine, dopamine, apelin, elebela, and nitric oxide were similar in ischemic stroke and in control groups (P>0.05). Strong correlations were found between renalase, cerebellin, and catecholamine levels in serum and urine (p <0.001) both in stroke patients and controls. There were also strong correlations between apelin, elabela, and NO levels in serum and urine (p <0.001) in the two groups.
Conclusion: Serum and urine cerebellin, renalase, epinephrine, norepinephrine, dopamine, apelin, elebela, and nitric oxide levels do not significantly change in the acute phase of ischemic stroke. Strong correlations among renalase, cerebellin, and catecholamines emphasize that these substances act together in healthy individuals and ischemic stroke patients. Similarly, strong correlations between apelin, elabela, and NO indicate that these agents act together in healthy subjects and patients with ischemic stroke.

Kaynakça

  • Katan M, Luft A. Global Burden of Stroke. Semin Neurol. 2018;38(2):208-211
  • Struijs JN, van Genugten ML, Evers SM, Ament AJ, Baan CA, van den Bos GA. Future costs of strokein the : theimpact of stroke services. Int J Technol Assess Health Care. 2006;22(04):518–524
  • Zerna C, Thomalla G, Campbell BCV, Rha JH, Hill MD. Current practice and future directions in the diagnosis and acute treatment of ischaemic stroke. Lancet. 201;392(10154):1247-1256.
  • Rabinstein AA. Treatment of Acute Ischemic Stroke. Continuum (Minneap Minn). 2017;23(1, Cerebrovascular Disease):62-81.
  • Patel RAG, McMullen PW. Neuroprotection in the Treatment of Acute Ischemic Stroke. Prog Cardiovasc Dis. 2017;59(6):542-548.
  • Lundberg U. Stress hormones in health and illness: the roles of work and gender. Psychoneuroendocrinology. 2005;30(10):1017-1021.
  • Goldstein DS, Eisenhofer G, Kopin IJ. Clinical catecholamine neurochemistry: a legacy of Julius Axelrod. Cell Mol Neurobiol. 2006;26(4-6):695-702.
  • Mazzocchi G, Andreis PG, De Caro R, Aragona F, Gottardo L, Nussdorfer GG. Cerebellin enhances in vitro secretory activity of human adrenal gland. J Clin Endocrinol Metab. 1999;84(2):632-635.
  • Rucinski M, Malendowicz LK. Precerebellin-related genes and precerebellin 1 peptide in endocrine glands of the rat-pattern of their expression. Int J Mol Med. 2009;23(1):113-119.
  • Strowski MZ, Kaczmarek P, Mergler S, Wiedenmann B, Domin D, Szwajkowski P, et al. Insulinostatic activity of cerebellin-evidence from in vivo and in vitro studies in rats. Regul Pept. 2009;157(1-3):19-24.
  • Satoh F, Takahashi K, Murakami O, Totsune K, Ohneda M, Mizuno Y, et al. Cerebellin and cerebellin mRNA in the human brain, adrenal glands and the tumour tissues of adrenal tumour, ganglioneuroblastoma and neuroblastoma. J Endocrinol. 1997;154(1):27-34.
  • Aydın S. Can cerebellin and renalase measurements contribute to the elimination of false positive results in pheochromocytoma and paraganglioma diagnoses? Med Hypotheses 2017;107:64.
  • Tokinoya K, Shiromoto J, Sugasawa T, Yoshida Y, Aoki K, Nakagawa Y, Ohmori H, Takekoshi K. Influence of acute exercise on renalase and its regulatory mechanism. Life Sci. 2018;210:235-242.
  • Wang F, Xing T, Li J, Bai M, Hu R, Zhao Z, et al. Renalase's expression and distribution in renal tissue and cells. PLoS One. 2012;7(10):e46442.
  • Zhang Y, Wang Y, Lou Y, Luo M, Lu Y, Li Z,et al. Elabela, a newly discovered APJ ligand: Similarities and differences with Apelin. Peptides. 2018;109:23-32.
  • Marsault E, Llorens-Cortes C, Iturrioz X, Chun HJ, Lesur O, Oudit GY, Auger-Messier M. The apelinergic system: a perspective on challenges and opportunities in cardiovascular and metabolic disorders. Ann N Y Acad Sci. 2019 Nov;1455(1):12-33.
  • Aydin S. A short history, principles, and types of ELISA, and our laboratory experience with peptide/protein analyses using ELISA. Peptides. 2015;72:4-15.
  • Fassbender K, Schmidt R, Mössner R, Daffertshofer M, Hennerici M. Pattern of activation of the hypothalamic-pituitary-adrenal axis in acute stroke. Relation to acute confusional state, extent of brain damage, and clinical outcome. Stroke. 1994;25(6):1105-1118.
  • Sternberg Z, Schaller B. Central Noradrenergic Agonists in the Treatment of Ischemic Stroke-an Overview. Transl Stroke Res. 2020;11(2):165-184.
  • Feibel JH, Hardy PM, Campbell RG, Goldstein MN, Joynt RJ. Prognostic value of the stress response following stroke. JAMA. 1977;238(13):1374-1376.
  • Olsson T. Urinary free cortisol excretion shortly after ischaemic stroke. J Intern Med. 1990;228(2):177-181.
  • Mracsko E, Liesz A, Karcher S, Zorn M, Bari F, Veltkamp R. Differential effects of sympathetic nervous system and hypothalamic-pituitary-adrenal axis on systemic immune cells after severe experimental stroke. Brain Behav Immun. 2014;41:200-209.
  • Liesz A, Rüger H, Purrucker J, Zorn M, Dalpke A, Möhlenbruch M, et al. Stress mediators and immune dysfunction in patients with acute cerebrovascular diseases. PLoS One. 2013;8(9):e74839.
  • Oto J, Suzue A, Inui D, Fukuta Y, Hosotsubo K, Torii M, et al. Plasma proinflammatory and anti-inflammatory cytokine and catecholamine concentrations as predictors of neurological outcome in acute stroke patients. J Anesth. 2008;22(3):207-212.
  • Sharma JC, Ross I, Vassallo M. Cardio-protection in acute stroke. Int J Stroke. 2007;2(4):299-301.
  • Huck JH, Freyer D, Böttcher C, Mladinov M, Muselmann-Genschow C, Thielke M, et al. De novo expression of dopamine D2 receptors on microglia after stroke. J Cereb Blood Flow Metab. 2015;35(11):1804-1811.
  • Scheidtmann K, Fries W, Müller F, Koenig E. Effect of levodopa in combination with physiotherapy on functional motor recovery after stroke: a prospective, randomised, double-blind study. Lancet. 2001;358(9284):787-990.
  • Rösser N, Heuschmann P, Wersching H, Breitenstein C, Knecht S, Flöel A. Levodopa improves procedural motor learning in chronic stroke patients. Arch Phys Med Rehabil. 2008;89(9):1633-1641.
  • Toner CC, Stamford JA. 'Real time' measurement of dopamine release in an in vitro model of neostriatal ischaemia. J Neurosci Methods. 1996;67(2):133-40.
  • Lin L, Sun D, Chang J, Ma M, Zhou X, Zhao M, et al. Cocaine‑ and amphetamine‑regulated transcript (CART) is associated with dopamine and is protective against ischemic stroke. Mol Med Rep. 2018;18(3):3298-3304.
  • Malyszko J, Bachorzewska-Gajewska H, Dobrzycki S. Renalase, kidney and cardiovascular disease: are they related or just coincidentally associated? Adv Med Sci. 2015;60(1):41-49.
  • Wang Y, Safirstein R, Velazquez H, Guo XJ, Hollander L, Chang J, et al. Extracellular renalase protects cells and organs by outside-in signalling. J Cell Mol Med. 2017;21(7):1260-1265. Lemiesz M, Tenderenda-Banasiuk E, Sosnowska D, Taranta-Janusz K, Wasilewska A. Serum Renalase Levels in Adolescents with Primary Hypertension. Pediatr Cardiol. 2018;39(6):1258-1264.
  • Wang Y, Lv YB, Chu C, Wang M, Xie BQ, Wang L, et al. Plasma Renalase is Not Associated with Blood Pressure and Brachial-Ankle Pulse Wave Velocity in Chinese Adults With Normal Renal Function. Kidney Blood Press Res. 2016;41(6):837-847.
  • Zbroch E, Musialowska D, Koc-Zorawska E, Malyszko J. Age influence on renalase and catecholamines concentration in hypertensive patients, including maintained dialysis. Clin Interv Aging. 2016;11:1545-1550.
  • Zhang R, Li X, Liu N, Guo X, Liu W, Ning C, et al. An association study on renalase polymorphisms and ischemic stroke in a Chinese population. Neuromolecular Med. 2013;15(2):396-404.
  • Malyszko J, Koc-Zorawska E, Malyszko JS, Kozminski P, Zbroch E, Mysliwiec M. Renalase, stroke, and hypertension in hemodialyzed patients. Ren Fail. 2012;34(6):727-731.
  • Hennebry SC, Eikelis N, Socratous F, Desir G, Lambert G, Schlaich M. Renalase, a novel soluble FAD-dependent protein, is synthesized in the brain and peripheral nerves. Mol Psychiatry. 2010;15(3):234-236.
  • Lee SJ, Uemura T, Yoshida T, Mishina M. GluRδ2 assembles four neurexins into trans-synaptic triad to trigger synapse formation. J Neurosci. 2012;32(13):4688-4701.
  • Otsuka S, Konno K, Abe M, Motohashi J, Kohda K, Sakimura K, et al. Roles of Cbln1 in Non-Motor Functions of Mice. J Neurosci. 2016;36(46):11801-11816.
  • Hochól A, Neri G, Majchrzak M, Ziolkowska A, Nussdorfer GG, Malendowicz LK. Prolonged cerebellin administration inhibits the growth, but enhances steroidogenic capacity of rat adrenal cortex. Endocr Res. 2001;27(1-2):11-17.
  • Albertin G, Malendowicz LK, Macchi C, Markowska A, Nussdorfer GG. Cerebellin stimulates the secretory activity of the rat adrenal gland: in vitro and in vivo studies. Neuropeptides. 2000;34(1):7-11.
  • Montaner J, Mendioroz M, Delgado P, García-Berrocoso T, Giralt D, Merino C, et al. Differentiating ischemic from hemorrhagic stroke using plasma biomarkers: the S100B/RAGE pathway. J Proteomics. 2012;75(15):4758-4765.
  • Wu Y, Wang X, Zhou X, Cheng B, Li G, Bai B. Temporal Expression of Apelin/Apelin Receptor in Ischemic Stroke and its Therapeutic Potential. Front Mol Neurosci. 2017;10:1.
  • Wu F, Qiu J, Fan Y, Zhang Q, Cheng B, Wu Y, et al. Apelin-13 attenuates ER stress-mediated neuronal apoptosis by activating Gα(i)/Gα(q)-CK2 signaling in ischemic stroke. Exp Neurol. 2018;302:136-144.
  • Gu Q, Zhai L, Feng X, Chen J, Miao Z, Ren L, et al. Apelin-36, a potent peptide, protects against ischemic brain injury by activating the PI3K/Akt pathway. Neurochem Int. 2013;63(6):535-540.
  • Yang P, Maguire JJ, Davenport AP. Apelin, Elabela/Toddler, and biased agonists as novel therapeutic agents in the cardiovascular system. Trends Pharmacol Sci. 2015;36(9):560-567.
  • Jiang W, Hu W, Ye L, Tian Y, Zhao R, Du J, et al. Contribution of Apelin-17 to Collateral Circulation Following Cerebral Ischemic Stroke. Transl Stroke Res. 2019;10(3):298-307.
  • Shin K, Kenward C, Rainey JK. Apelinergic System Structure and Function. Compr Physiol. 2017;8(1):407-450.
  • Marsault E, Llorens-Cortes C, Iturrioz X, Chun HJ, Lesur O, Oudit GY, et al. The apelinergic system: a perspective on challenges and opportunities in cardiovascular and metabolic disorders. Ann N Y Acad Sci. 2019;1455(1):12-33.
  • Li Y, Yang X, Ouyang S, He J, Yu B, Lin X, et al. Declined circulating Elabela levels in patients with essential hypertension and its association with impaired vascular function: A preliminary study. Clin Exp Hypertens. 2020;42(3):239-243.
  • Narne P, Pandey V, Phanithi PB. Role of Nitric Oxide and Hydrogen Sulfide in Ischemic Stroke and the Emergent Epigenetic Underpinnings. Mol Neurobiol. 2019;56(3):1749-1769.
  • Chen ZQ, Mou RT, Feng DX, Wang Z, Chen G. The role of nitric oxide in stroke. Med Gas Res. 2017;7(3):194-203.
  • Liu H, Li J, Zhao F, Wang H, Qu Y, Mu D. Nitric oxide synthase in hypoxic or ischemic brain injury. Rev Neurosci. 2015;26(1):105-117.

Akut İskemik İnme Hastalarında Serum ve İdrar Katekolaminerjik ve Apelinerjik Sistem Üyelerinin Düzeyleri

Yıl 2023, Cilt: 18 Sayı: 3, 86 - 94, 20.11.2023
https://doi.org/10.17517/ksutfd.1168625

Öz

Amaç: Akut iskemik inmeli hastalarda ve sağlıklı kontrollerde katekolaminerjik sistem üyeleri renalaz, serebellin ve bunların substratları epinefrin, norepinefrin ve dopamin ile apelinerjik sistem üyeleri apelin, elabela ve nitrik oksit düzeylerinin kan ve idrarda karşılaştırılması.
Gereç ve Yöntemler: Akut iskemik inmeli 42 hasta ile yaş ve cinsiyet açısından eşleştirilmiş 42 sağlıklı kontrol çalışmaya dahil edildi. Kan ve idrar örnekleri akut inme klinik belirtilerinin başlangıcından sonraki ilk 24 saat içinde eş zamanlı olarak toplandı ve ELISA yöntemi kullanılarak ölçüldü.
Bulgular: İskemik inme ve kontrol gruplarında serum ve idrar serebellin, renalaz, epinefrin, norepinefrin, dopamin, apelin, elebela ve nitrik oksit düzeyleri benzerdi (P>0.05). Hem inmeli hastalarda hem de kontrollerde serum ve idrarda renalaz, serebellin ve katekolamin düzeyleri arasında güçlü korelasyonlar bulundu (p <0.001). İki grupta da serum ve idrarda apelin, elabela ve NO düzeyleri arasında güçlü korelasyonlar vardı (p<0.001).
Sonuç: İskemik inmenin akut fazında serum ve idrar serebellin, renalaz, epinefrin, norepinefrin, dopamin, apelin, elebela ve nitrik oksit düzeyleri önemli ölçüde değişmemektedir. Renalaz, serebellin ve katekolaminler arasındaki güçlü korelasyonlar, bu maddelerin sağlıklı bireylerde ve iskemik inmeli hastalarda birlikte hareket ettiğini vurgulamaktadır. Benzer şekilde, apelin, elabela ve NO arasındaki güçlü korelasyonlar, bu ajanların sağlıklı kişilerde ve iskemik inmeli hastalarda birlikte hareket ettiğini göstermektedir.

Kaynakça

  • Katan M, Luft A. Global Burden of Stroke. Semin Neurol. 2018;38(2):208-211
  • Struijs JN, van Genugten ML, Evers SM, Ament AJ, Baan CA, van den Bos GA. Future costs of strokein the : theimpact of stroke services. Int J Technol Assess Health Care. 2006;22(04):518–524
  • Zerna C, Thomalla G, Campbell BCV, Rha JH, Hill MD. Current practice and future directions in the diagnosis and acute treatment of ischaemic stroke. Lancet. 201;392(10154):1247-1256.
  • Rabinstein AA. Treatment of Acute Ischemic Stroke. Continuum (Minneap Minn). 2017;23(1, Cerebrovascular Disease):62-81.
  • Patel RAG, McMullen PW. Neuroprotection in the Treatment of Acute Ischemic Stroke. Prog Cardiovasc Dis. 2017;59(6):542-548.
  • Lundberg U. Stress hormones in health and illness: the roles of work and gender. Psychoneuroendocrinology. 2005;30(10):1017-1021.
  • Goldstein DS, Eisenhofer G, Kopin IJ. Clinical catecholamine neurochemistry: a legacy of Julius Axelrod. Cell Mol Neurobiol. 2006;26(4-6):695-702.
  • Mazzocchi G, Andreis PG, De Caro R, Aragona F, Gottardo L, Nussdorfer GG. Cerebellin enhances in vitro secretory activity of human adrenal gland. J Clin Endocrinol Metab. 1999;84(2):632-635.
  • Rucinski M, Malendowicz LK. Precerebellin-related genes and precerebellin 1 peptide in endocrine glands of the rat-pattern of their expression. Int J Mol Med. 2009;23(1):113-119.
  • Strowski MZ, Kaczmarek P, Mergler S, Wiedenmann B, Domin D, Szwajkowski P, et al. Insulinostatic activity of cerebellin-evidence from in vivo and in vitro studies in rats. Regul Pept. 2009;157(1-3):19-24.
  • Satoh F, Takahashi K, Murakami O, Totsune K, Ohneda M, Mizuno Y, et al. Cerebellin and cerebellin mRNA in the human brain, adrenal glands and the tumour tissues of adrenal tumour, ganglioneuroblastoma and neuroblastoma. J Endocrinol. 1997;154(1):27-34.
  • Aydın S. Can cerebellin and renalase measurements contribute to the elimination of false positive results in pheochromocytoma and paraganglioma diagnoses? Med Hypotheses 2017;107:64.
  • Tokinoya K, Shiromoto J, Sugasawa T, Yoshida Y, Aoki K, Nakagawa Y, Ohmori H, Takekoshi K. Influence of acute exercise on renalase and its regulatory mechanism. Life Sci. 2018;210:235-242.
  • Wang F, Xing T, Li J, Bai M, Hu R, Zhao Z, et al. Renalase's expression and distribution in renal tissue and cells. PLoS One. 2012;7(10):e46442.
  • Zhang Y, Wang Y, Lou Y, Luo M, Lu Y, Li Z,et al. Elabela, a newly discovered APJ ligand: Similarities and differences with Apelin. Peptides. 2018;109:23-32.
  • Marsault E, Llorens-Cortes C, Iturrioz X, Chun HJ, Lesur O, Oudit GY, Auger-Messier M. The apelinergic system: a perspective on challenges and opportunities in cardiovascular and metabolic disorders. Ann N Y Acad Sci. 2019 Nov;1455(1):12-33.
  • Aydin S. A short history, principles, and types of ELISA, and our laboratory experience with peptide/protein analyses using ELISA. Peptides. 2015;72:4-15.
  • Fassbender K, Schmidt R, Mössner R, Daffertshofer M, Hennerici M. Pattern of activation of the hypothalamic-pituitary-adrenal axis in acute stroke. Relation to acute confusional state, extent of brain damage, and clinical outcome. Stroke. 1994;25(6):1105-1118.
  • Sternberg Z, Schaller B. Central Noradrenergic Agonists in the Treatment of Ischemic Stroke-an Overview. Transl Stroke Res. 2020;11(2):165-184.
  • Feibel JH, Hardy PM, Campbell RG, Goldstein MN, Joynt RJ. Prognostic value of the stress response following stroke. JAMA. 1977;238(13):1374-1376.
  • Olsson T. Urinary free cortisol excretion shortly after ischaemic stroke. J Intern Med. 1990;228(2):177-181.
  • Mracsko E, Liesz A, Karcher S, Zorn M, Bari F, Veltkamp R. Differential effects of sympathetic nervous system and hypothalamic-pituitary-adrenal axis on systemic immune cells after severe experimental stroke. Brain Behav Immun. 2014;41:200-209.
  • Liesz A, Rüger H, Purrucker J, Zorn M, Dalpke A, Möhlenbruch M, et al. Stress mediators and immune dysfunction in patients with acute cerebrovascular diseases. PLoS One. 2013;8(9):e74839.
  • Oto J, Suzue A, Inui D, Fukuta Y, Hosotsubo K, Torii M, et al. Plasma proinflammatory and anti-inflammatory cytokine and catecholamine concentrations as predictors of neurological outcome in acute stroke patients. J Anesth. 2008;22(3):207-212.
  • Sharma JC, Ross I, Vassallo M. Cardio-protection in acute stroke. Int J Stroke. 2007;2(4):299-301.
  • Huck JH, Freyer D, Böttcher C, Mladinov M, Muselmann-Genschow C, Thielke M, et al. De novo expression of dopamine D2 receptors on microglia after stroke. J Cereb Blood Flow Metab. 2015;35(11):1804-1811.
  • Scheidtmann K, Fries W, Müller F, Koenig E. Effect of levodopa in combination with physiotherapy on functional motor recovery after stroke: a prospective, randomised, double-blind study. Lancet. 2001;358(9284):787-990.
  • Rösser N, Heuschmann P, Wersching H, Breitenstein C, Knecht S, Flöel A. Levodopa improves procedural motor learning in chronic stroke patients. Arch Phys Med Rehabil. 2008;89(9):1633-1641.
  • Toner CC, Stamford JA. 'Real time' measurement of dopamine release in an in vitro model of neostriatal ischaemia. J Neurosci Methods. 1996;67(2):133-40.
  • Lin L, Sun D, Chang J, Ma M, Zhou X, Zhao M, et al. Cocaine‑ and amphetamine‑regulated transcript (CART) is associated with dopamine and is protective against ischemic stroke. Mol Med Rep. 2018;18(3):3298-3304.
  • Malyszko J, Bachorzewska-Gajewska H, Dobrzycki S. Renalase, kidney and cardiovascular disease: are they related or just coincidentally associated? Adv Med Sci. 2015;60(1):41-49.
  • Wang Y, Safirstein R, Velazquez H, Guo XJ, Hollander L, Chang J, et al. Extracellular renalase protects cells and organs by outside-in signalling. J Cell Mol Med. 2017;21(7):1260-1265. Lemiesz M, Tenderenda-Banasiuk E, Sosnowska D, Taranta-Janusz K, Wasilewska A. Serum Renalase Levels in Adolescents with Primary Hypertension. Pediatr Cardiol. 2018;39(6):1258-1264.
  • Wang Y, Lv YB, Chu C, Wang M, Xie BQ, Wang L, et al. Plasma Renalase is Not Associated with Blood Pressure and Brachial-Ankle Pulse Wave Velocity in Chinese Adults With Normal Renal Function. Kidney Blood Press Res. 2016;41(6):837-847.
  • Zbroch E, Musialowska D, Koc-Zorawska E, Malyszko J. Age influence on renalase and catecholamines concentration in hypertensive patients, including maintained dialysis. Clin Interv Aging. 2016;11:1545-1550.
  • Zhang R, Li X, Liu N, Guo X, Liu W, Ning C, et al. An association study on renalase polymorphisms and ischemic stroke in a Chinese population. Neuromolecular Med. 2013;15(2):396-404.
  • Malyszko J, Koc-Zorawska E, Malyszko JS, Kozminski P, Zbroch E, Mysliwiec M. Renalase, stroke, and hypertension in hemodialyzed patients. Ren Fail. 2012;34(6):727-731.
  • Hennebry SC, Eikelis N, Socratous F, Desir G, Lambert G, Schlaich M. Renalase, a novel soluble FAD-dependent protein, is synthesized in the brain and peripheral nerves. Mol Psychiatry. 2010;15(3):234-236.
  • Lee SJ, Uemura T, Yoshida T, Mishina M. GluRδ2 assembles four neurexins into trans-synaptic triad to trigger synapse formation. J Neurosci. 2012;32(13):4688-4701.
  • Otsuka S, Konno K, Abe M, Motohashi J, Kohda K, Sakimura K, et al. Roles of Cbln1 in Non-Motor Functions of Mice. J Neurosci. 2016;36(46):11801-11816.
  • Hochól A, Neri G, Majchrzak M, Ziolkowska A, Nussdorfer GG, Malendowicz LK. Prolonged cerebellin administration inhibits the growth, but enhances steroidogenic capacity of rat adrenal cortex. Endocr Res. 2001;27(1-2):11-17.
  • Albertin G, Malendowicz LK, Macchi C, Markowska A, Nussdorfer GG. Cerebellin stimulates the secretory activity of the rat adrenal gland: in vitro and in vivo studies. Neuropeptides. 2000;34(1):7-11.
  • Montaner J, Mendioroz M, Delgado P, García-Berrocoso T, Giralt D, Merino C, et al. Differentiating ischemic from hemorrhagic stroke using plasma biomarkers: the S100B/RAGE pathway. J Proteomics. 2012;75(15):4758-4765.
  • Wu Y, Wang X, Zhou X, Cheng B, Li G, Bai B. Temporal Expression of Apelin/Apelin Receptor in Ischemic Stroke and its Therapeutic Potential. Front Mol Neurosci. 2017;10:1.
  • Wu F, Qiu J, Fan Y, Zhang Q, Cheng B, Wu Y, et al. Apelin-13 attenuates ER stress-mediated neuronal apoptosis by activating Gα(i)/Gα(q)-CK2 signaling in ischemic stroke. Exp Neurol. 2018;302:136-144.
  • Gu Q, Zhai L, Feng X, Chen J, Miao Z, Ren L, et al. Apelin-36, a potent peptide, protects against ischemic brain injury by activating the PI3K/Akt pathway. Neurochem Int. 2013;63(6):535-540.
  • Yang P, Maguire JJ, Davenport AP. Apelin, Elabela/Toddler, and biased agonists as novel therapeutic agents in the cardiovascular system. Trends Pharmacol Sci. 2015;36(9):560-567.
  • Jiang W, Hu W, Ye L, Tian Y, Zhao R, Du J, et al. Contribution of Apelin-17 to Collateral Circulation Following Cerebral Ischemic Stroke. Transl Stroke Res. 2019;10(3):298-307.
  • Shin K, Kenward C, Rainey JK. Apelinergic System Structure and Function. Compr Physiol. 2017;8(1):407-450.
  • Marsault E, Llorens-Cortes C, Iturrioz X, Chun HJ, Lesur O, Oudit GY, et al. The apelinergic system: a perspective on challenges and opportunities in cardiovascular and metabolic disorders. Ann N Y Acad Sci. 2019;1455(1):12-33.
  • Li Y, Yang X, Ouyang S, He J, Yu B, Lin X, et al. Declined circulating Elabela levels in patients with essential hypertension and its association with impaired vascular function: A preliminary study. Clin Exp Hypertens. 2020;42(3):239-243.
  • Narne P, Pandey V, Phanithi PB. Role of Nitric Oxide and Hydrogen Sulfide in Ischemic Stroke and the Emergent Epigenetic Underpinnings. Mol Neurobiol. 2019;56(3):1749-1769.
  • Chen ZQ, Mou RT, Feng DX, Wang Z, Chen G. The role of nitric oxide in stroke. Med Gas Res. 2017;7(3):194-203.
  • Liu H, Li J, Zhao F, Wang H, Qu Y, Mu D. Nitric oxide synthase in hypoxic or ischemic brain injury. Rev Neurosci. 2015;26(1):105-117.
Toplam 53 adet kaynakça vardır.

Ayrıntılar

Birincil Dil İngilizce
Konular Sağlık Kurumları Yönetimi
Bölüm Araştırma Makaleleri
Yazarlar

Özlem Güler 0000-0002-1444-7730

Buket Tuğan Yıldız 0000-0001-6783-2336

Hakan Hakkoymaz 0000-0002-8568-8283

Süleyman Aydın 0000-0001-6162-3250

Meltem Yardım 0000-0002-0348-6312

Erken Görünüm Tarihi 10 Kasım 2023
Yayımlanma Tarihi 20 Kasım 2023
Gönderilme Tarihi 31 Ağustos 2022
Kabul Tarihi 4 Ekim 2022
Yayımlandığı Sayı Yıl 2023 Cilt: 18 Sayı: 3

Kaynak Göster

AMA Güler Ö, Tuğan Yıldız B, Hakkoymaz H, Aydın S, Yardım M. Levels of Serum and Urine Catecholaminergic and Apelinergic System Members in Acute Ischemic Stroke Patients. KSÜ Tıp Fak Der. Kasım 2023;18(3):86-94. doi:10.17517/ksutfd.1168625